Business Overview: ClearPoint Neuro, Inc. (NASDAQ: CLPT)

---

Executive Summary

ClearPoint Neuro, Inc. is a commercial-stage medical device company founded in 1998 that develops platforms for minimally invasive neurosurgical procedures, alongside a growing biologics and drug delivery services business supporting pharmaceutical partners' gene and cell therapy programs. The company's flagship ClearPoint System enables MRI-guided placement of deep brain stimulation electrodes, biopsy needles, laser catheters, and direct pharmaceutical infusion into brain tissue.

ClearPoint reported $37 million in revenue for fiscal year 2025 and issued 2026 guidance, reflecting continued growth across both its neurosurgery navigation business and its expanding drug delivery services segment.

---

1. Core Business Model & How They Work

ClearPoint operates a razor/razorblade-style model in its core neurosurgery business, combined with a fee-for-service biologics/drug delivery consulting business serving external pharmaceutical partners.

Key Operational Drivers

1. Capital Equipment Placement, Disposable-Driven Revenue: The company prices its reusable ClearPoint System hardware competitively to secure hospital installations, then generates high-margin recurring revenue from disposable components (SmartFrame trajectory devices, SmartFlow cannulas) used in each procedure.
2. Drug Delivery Services for Pharma Partners: ClearPoint provides preclinical development and consulting services to over 60 pharmaceutical and biotech collaborators developing gene and cell therapies that require precise neural drug delivery — a business that scales with the broader gene therapy industry's growth.
3. Regulatory Milestones Expanding Addressable Procedures: The 2024 FDA clearance of the SmartFrame OR Stereotactic System (enabling complete procedures in the operating room, not just an MRI suite) broadens the settings in which ClearPoint's technology can be used.
4. Strategic Partnerships: Exclusive commercialization rights for the ClearPoint Prism Laser Therapy System (developed with Clinical Laserthermia Systems) and a licensing relationship with Philips for brain imaging technology extend the company's addressable product line without fully organic R&D investment.

---

2. Business Segments

Neurosurgery Navigation & Therapy

The ClearPoint System platform (hardware, disposables, software) used for deep brain stimulation lead placement, biopsies, and laser ablation therapy (via the ClearPoint Prism system). Revenue here follows a capital-equipment-plus-disposables model.

Biologics & Drug Delivery Services

Preclinical development services and consulting for pharmaceutical and biotech partners developing therapies requiring precise neural/CNS drug delivery. PTC Therapeutics alone represents approximately 17% of drug delivery revenues, alongside a multi-year gene therapy collaboration with UCB Biopharma.

---

3. Product Portfolio

---

4. Competitive Landscape

ClearPoint competes against much larger, diversified medical device companies across its various product lines.

Key Competitors:

• Medtronic, Boston Scientific, Abbott — deep brain stimulation (DBS) systems
• Monteris Medical, Medtronic — laser ablation therapy
• Brainlab, Elekta — surgical navigation systems

Management acknowledges that competitors possess "substantially greater financial, manufacturing, marketing, and technical resources." ClearPoint's differentiation rests on its focused MRI-guided navigation platform and its growing role as an outsourced delivery-technology partner for pharmaceutical companies developing next-generation CNS therapies — a niche too specialized for most large medtech competitors to prioritize.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Installed Base Lock-In: Once a hospital installs the ClearPoint System, ongoing disposable purchases create a recurring, high-margin revenue stream with natural switching friction.
• Pharma Partnership Network: Relationships with 60+ pharmaceutical/biotech collaborators (including PTC Therapeutics and UCB Biopharma) position ClearPoint as an embedded partner in the emerging CNS gene therapy delivery ecosystem.
• Regulatory Clearances: Ongoing FDA clearances (e.g., SmartFrame OR) continuously expand the addressable use cases for the core platform.
• Focused Niche Expertise: Deep specialization in MRI-guided neurosurgical navigation is difficult for generalist medtech giants to replicate with equal focus.

Strategic Risks & Vulnerabilities

1. Scale Disadvantage: Competing against Medtronic, Boston Scientific, and Abbott means ClearPoint faces competitors with vastly greater R&D budgets and sales infrastructure.
2. Customer Concentration in Drug Delivery: PTC Therapeutics alone represents ~17% of drug delivery revenue, creating dependency risk if that relationship changes.
3. Reimbursement and Hospital Capital Budget Risk: Placement of new ClearPoint System units depends on hospital capital spending cycles, which can be deferred.
4. Gene Therapy Industry Dependence: The drug delivery services segment's growth is tied to the broader (still-maturing) gene and cell therapy industry's clinical and commercial success.

---

6. Financial Overview

---

7. Summary Conclusion

ClearPoint Neuro occupies a specialized niche within neurosurgical navigation and CNS drug delivery, competing against far larger medtech incumbents by focusing intensely on MRI-guided precision and by embedding itself as an outsourced delivery-technology partner for pharmaceutical companies developing gene and cell therapies. Its installed-base-plus-disposables model in neurosurgery, combined with a growing services business tied to the broader CNS gene therapy industry, gives it two distinct but related growth vectors. The company's small scale relative to Medtronic, Boston Scientific, and Abbott, along with meaningful customer concentration in its drug delivery segment, remain the primary risks to monitor as it scales toward broader profitability.